OliX PharmaceuticalsInc

226950 · KQ · Healthcare / Biotechnology

80,900.00KRW+400.00 (+0.50%)

Price History

Full chart

Market Stats

Previous Close80,500.00

Open82,500.00

Day Range80,100.00 – 86,600.00

52-Week Range84,300.00 – 217,000.00

Volume171.57K

Market Cap2.14T

P/E (TTM)0.00

Forward P/E0.00

EPS-616.70

Dividend Yield0.00%

Beta0.40

50-Day Avg103,058.00

200-Day Avg137,509.50

About

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepatitis; and OLX301D for subretinal fibrosis. The company has a license and collaboration agreement with Hansoh Pharmaceuticals; development collaboration with Korea Institute of Technology; and research collaboration with the University of Virginia. The company was formerly known as Biomolecular Therapeutics Inc. OliX Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Suwon-si, South Korea.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Dong-Ki Lee Ph.D.
Employees81
HeadquartersSuite 1014, Suwon-si, South Korea, Korea
Websitehttps://www.olixpharma.com

Leadership

Mr. Dong-Ki Lee Ph.D.CEO & Director · b. 1972
Jin Kim YoungMD & CFO
Ms. Young Hye BaekVice President of IP & Legal Affairs
Chunggil KangPresident of Management Dept · b. 1971
Joonhyun ParkManaging Director & Head of Research

Financials

Income Statement

Currency: KRW	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	391.90M	243.97M	302.00M	1.13B	2.47B	3.67B	9.32B	17.06B	5.68B	14.67B
Growth (%)	-	-37.75%	+23.79%	+274.28%	+118.90%	+48.50%	+153.66%	+83.09%	-66.73%	+158.35%
Cost of Revenue	-	32.40M	28.51M	19.26M	-	308.37M	-	-	-	-
Gross Profit	-	211.57M	273.49M	1.11B	2.47B	3.37B	9.32B	17.06B	5.68B	14.67B
Gross Margin	-	86.72%	90.56%	98.30%	100.00%	91.61%	100.00%	100.00%	100.00%	100.00%
Operating Expense	-	5.67B	8.51B	16.23B	18.72B	27.31B	31.70B	34.83B	44.29B	44.64B
Operating Income	-3.82B	-5.46B	-8.23B	-15.12B	-16.24B	-23.94B	-22.38B	-17.76B	-38.61B	-29.97B
Operating Margin	-975.19%	-2237.55%	-2726.47%	-1337.38%	-656.41%	-651.52%	-240.07%	-104.10%	-680.17%	-204.35%
EBITDA	-	-	-	-	-	-	-24.10B	-12.04B	-33.78B	-8.98B
EBITDA Margin	-	-	-	-	-	-	-258.60%	-70.53%	-595.07%	-61.22%
Net Income	-3.66B	-5.16B	-7.74B	-14.35B	-19.38B	-29.71B	-19.50B	-19.10B	-40.66B	-15.74B
Net Income Margin	-932.79%	-2116.65%	-2563.58%	-1269.79%	-783.44%	-808.70%	-209.17%	-111.94%	-716.18%	-107.33%
R&D	-	3.33B	5.08B	8.97B	9.48B	15.84B	17.38B	18.48B	19.54B	25.65B
R&D as % of Total Revenue	-	1366.59%	1682.92%	793.84%	383.07%	431.21%	186.46%	108.29%	344.12%	174.86%
Interest Expense	0	0	0	0	239.07M	2.48B	2.93B	3.49B	4.66B	1.82B
Interest Expense % of Total Revenue	0.00%	0.00%	0.00%	0.00%	9.66%	67.54%	31.44%	20.46%	82.11%	12.41%

Balance Sheet

Currency: KRW	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	15.15B	21.64B	55.64B	45.21B	78.58B	86.67B	132.65B	102.83B	71.25B	195.37B
Total Liabilities	2.59B	2.96B	698.94M	3.41B	33.29B	68.15B	66.74B	52.49B	53.40B	45.29B
Total Equity	12.56B	18.68B	54.94B	41.80B	45.29B	18.52B	65.91B	49.85B	17.85B	149.38B
Cash	629.02M	678.05M	2.81B	4.95B	11.33B	34.34B	4.93B	11.98B	3.89B	6.36B
Total Debt	1.40B	1.40B	-	206.93M	14.27B	-	-	-	-	-
Net Debt	-	-	-	-	2.68B	2.07B	34.30B	23.38B	34.56B	15.71B

Cash Flow

Currency: KRW	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-3.45B	-4.79B	-8.36B	-10.73B	-3.76B	-19.05B	-30.68B	-21.17B	-28.04B	-15.90B
Investing Cash Flow	-7.77B	-5.82B	-31.74B	12.59B	-31.42B	15.47B	-54.76B	34.37B	973.56M	-
Financing Cash Flow	9.95B	10.66B	42.26B	169.60M	41.66B	26.56B	56.05B	-6.11B	18.54B	-
Capital Expenditure	3.27B	1.26B	500.37M	1.01B	786.48M	1.29B	2.23B	9.07B	14.08B	1.86B
Free Cash Flow	-	-	-	-16.18B	-4.92B	-45.34B	-33.22B	-30.24B	-42.12B	-17.76B
FCF to OCF	-	-	-	150.78%	130.90%	237.95%	108.26%	142.84%	150.20%	111.68%

Earnings

Report Date	Aug 14, 2018	Nov 13, 2018	Jan 31, 2019	May 30, 2019	Aug 27, 2019	Nov 25, 2019	Jan 28, 2020	May 29, 2020	Aug 28, 2020	Nov 18, 2020	Jan 26, 2021	May 14, 2021	Aug 17, 2021	Nov 15, 2021	Feb 9, 2022	May 16, 2022	Aug 12, 2022	Nov 11, 2022	Feb 8, 2023	May 12, 2023	Aug 11, 2023	Nov 13, 2023	Mar 18, 2024	May 14, 2024	Aug 13, 2024	Nov 11, 2024	Mar 17, 2025	May 15, 2025	Aug 11, 2025	Nov 12, 2025	Mar 16, 2026	May 13, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	-411.00	-340.00	-131.00	-178.00	-258.74	-266.30	-394.62	-222.50	-353.50	-319.50	-565.59	-605.86	-369.78	-669.63	-526.25	-659.47	-624.55	-479.36	482.32	-509.02	-645.58	-345.96	199.43	-511.56	-577.99	-621.29	-701.81	-708.84	-465.34	-433.03	762.35	-439.87	-492.64
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	Pre-market	Pre-market	Pre-market	Pre-market	-

Key Statistics & Ratios

Market Cap2.14T

Enterprise Value1.95T

Trailing P/E0.00

Forward P/E0.00

Price / Sales156.83

Price / Book9.07

EPS-616.70

Book Value10,403.22

Revenue (TTM)13.64B

Gross Profit (TTM)13.30B

EBITDA-39.21B

Profit Margin-102.89%

Operating Margin-533.34%

Return on Equity-10.76%

Return on Assets-14.83%

Shares Outstanding22.75M

Shares Float18.88M

Beta0.40

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Dec 3, 20202:1